首页> 外国专利> RITUXIMAB INDUCTION THERAPY FOLLOWED BY GLATIRAMER ACETATE THERAPY

RITUXIMAB INDUCTION THERAPY FOLLOWED BY GLATIRAMER ACETATE THERAPY

机译:醋酸格拉默治疗后的利妥昔单抗诱导治疗

摘要

The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. The present invention also provides a method of treating a subject afflicted with an immune disease, comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject wherein the amounts are effective to treat the subject, and wherein the immune disease is an autoimmune disease, an arthritic condition, a demyelinating disease, an inflammatory disease, multiple sclerosis, relapsing-remitting multiple sclerosis, diabetes mellitus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, or systemic lupus erythematosus.
机译:本发明提供了一种治疗患有多发性硬化症形式或表现出临床分离的综合征的对象的方法,该方法包括向该对象定期施用至少两次的量的利妥昔单抗,然后向该对象定期施用一定量的醋酸格拉替雷,其中所述量可有效治疗受试者。本发明还提供了一种治疗患有免疫疾病的受试者的方法,该方法包括向该受试者定期给予至少两次利妥昔单抗的量,然后向该受试者定期给予一定量的醋酸格拉替雷,其中该量对治疗个体,其中免疫疾病是自身免疫疾病,关节炎病,脱髓鞘疾病,炎性疾病,多发性硬化症,复发-缓解型多发性硬化症,糖尿病,牛皮癣,类风湿性关节炎,炎性肠病,克罗恩病,或系统性红斑狼疮。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号